WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
Frances Haugen’s lessons as a Facebook whistleblower
Best Of: Tracking the mysterious rise of a UAE company
How a big biotech’s start-up gamble went wrong
The downfall of a UK hedge fund titan
Is crypto a security, bro?
Is Africa’s debt cycle unbreakable?
Introducing Unhedged
Libor's long goodbye
Best Of: Inside Johnson & Johnson’s bankruptcy two-step
Does anyone want a digital euro?
Why companies don't want to list in the UK anymore
Night School, Class 5: How to read the markets
Can Intel bounce back?
Night School, Class 4: ESG reshapes the boardroom
How EY’s Project Everest collapsed
Night School, Class 3: Big Tech vs the insurgents
FT Weekend: The secret gamblers using AI to hack horse racing
Night School, Class 2: Why high inflation persists
Why Apple can’t leave China
Night School, Class 1: Green energy’s big year
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly